Navigation Links
Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:9/20/2011

NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0617093/Neuropathic-Pain-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Hardware,_Home_Improvement_&_Furnishing_Stores

Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Neuropathic Pain Therapeutics market. The report identifies the key trends shaping and driving the global Neuropathic Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Neuropathic Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Neuropathic Pain Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Neuropathic Pain Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Neuropathic Pain Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Neuropathic Pain Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Neuropathic Pain Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Neuropathic Pain Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Neuropathic Pain Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Neuropathic Pain Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Neuropathic Pain Therapeutics - Introduction 7

2.1 Disease Overview 7

2.1.1 Chronic Pain is Further Divided Into 8

2.2 Etiology and Pathophysiology 9

2.3 Signs and Symptoms 12

2.4 Epidemiology 13

2.5 Diagnosis 14

2.5.1 McGill Pain Questionnaire (MPQ) 15

2.5.2 Neuropathic Pain Scale (NPS) 15

2.5.3 Quantitative Sensory Testing (QST) 15

2.6 Treatment and Management Pattern 15

2.7 Referral Pathway 17

2.8 GlobalData Pipeline Report Guidance 18

3 Neuropathic Pain Therapeutics - Market Characterization 19

3.1 Neuropathic Pain Therapeutics Market Size (2005–2010) – Global 19

3.2 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Global 20

3.3 Neuropathic Pain Therapeutics Market Size (2005–2010) – The US 21

3.4 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – The US 22

3.5 Neuropathic Pain Therapeutics Market Size (2005–2010) – The UK 23

3.6 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – The UK 24

3.7 Neuropathic Pain Therapeutics Market Size (2005–2010) – France 25

3.8 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – France 26

3.9 Neuropathic Pain Therapeutics Market Size (2005–2010) – Germany 27

3.10 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Germany 28

3.11 Neuropathic Pain Therapeutics Market Size (2005–2010) – Italy 29

3.12 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Italy 30

3.13 Neuropathic Pain Therapeutics Market Size (2005–2010) – Spain 31

3.14 Neuropathic Pain Therapeutics Market Forecast (2010–2018) – Spain 32

3.15 Neuropathic Pain Therapeutics Market Size (2005–2010) – Japan 33

3.16 Neuropathic Pain Therapeutics Market Size (2010–2018) – Japan 34

3.17 Drivers and Barriers for the Neuropathic Pain Therapeutics Market 35

3.17.1 Drivers for Neuropathic Pain Market 35

3.17.2 Barriers for Neuropathic Pain Market 35

3.18 Opportunity and Unmet Need Analysis 35

3.19 Key Takeaway 37

4 Neuropathic Pain Therapeutics - Competitive Assessment 38

4.1 Overview 38

4.2 Strategic Competitor Assessment 38

4.3 Product Profiles for the Major Marketed Products in the Neuropathic Pain Therapeutics Market 39

4.3.1 Lyrica (pregabalin) 39

4.3.2 Cymbalta (duloxetine) 40

4.3.3 Lidoderm (lidocaine patch 5%) 42

4.3.4 Neurontin (gabapentin) 43

4.3.5 Qutenza (capsaicin) 8% Patch 44

4.4 Key Takeaway 46

5 Global Neuropathic Pain Market - Pipeline Assessment 47

5.1 Overview 47

5.2 Strategic Pipeline Assessment 47

5.3 Neuropathic Pain Therapeutics Pipeline – Pipeline by Phases of Development 47

5.3.1 Neuropathic Pain Therapeutics – Regulatory Filed Products 48

5.3.2 Neuropathic Pain Therapeutics – Phase III Pipeline 48

5.3.3 Neuropathic Pain Therapeutics – Phase II Pipeline 49

5.3.4 Neuropathic Pain Therapeutics – Phase I Pipeline 50

5.3.5 Neuropathic Pain Market – Discovery and Pre-Clinical Pipeline 51

5.3.6 Technology Trends Analytic Framework 53

5.4 Neuropathic Pain Therapeutics Market – Pipeline by Mechanism of Action 55

5.5 Neuropathic Pain Therapeutics – Promising Drugs Under Clinical Development 56

5.6 Molecule Profile for Promising Drugs under Clinical Development 57

5.6.1 AVP-923 (Zenvia) 57

5.6.2 Fentora (fentanyl buccal tablet) 58

5.6.3 Nucynta ER (tapentadol) 59

5.6.4 AS-3201 (ranirestat) 60

5.7 Key Takeaway 61

6 Neuropathic Pain Therapeutics: Clinical Trials Mapping 62

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 62

6.2 Clinical Trials by Phase 63

6.3 Clinical Trials by Trial Status 64

6.4 Clinical Trials by Sponsors 65

6.5 Top Companies Participating in Neuropathic Pain Therapeutics Clinical Trials 67

7 Neuropathic Pain Therapeutics - Strategic Assessment 68

7.1 Key Events Impacting the Future Market 68

7.2 Neuropathic Pain Therapeutics: Implications for Future Market Competition 69

8 Neuropathic Pain Therapeutics - Future Players 71

8.1 Introduction 71

8.2 Company Profiles 72

8.2.1 Pfizer Inc. 72

8.2.2 Grunenthal GmbH 76

8.2.3 Avanir Pharmaceuticals 78

8.2.4 Cephalon Inc. 79

8.2.5 Endo Pharmaceuticals 82

8.2.6 Dainippon Sumitomo Pharma Co., Ltd. 84

8.2.7 NeurogesX Inc. 88

8.2.8 Other Companies in the Neuropathic Pain Therapeutics Market 91

9 Neuropathic Pain Therapeutics - Licensing and Partnership Deals 99

10 Neuropathic Pain Therapeutics - Appendix 106

10.1 Market Definitions 106

10.2 Abbreviations 106

10.3 Research Methodology 107

10.3.1 Coverage 108

10.3.2 Secondary Research 108

10.3.3 Forecasting 108

10.3.4 Primary Research 111

10.3.5 Expert Panel Validation 111

10.4 Contact Us 111

10.5 Disclaimer 111

10.6 Bibliography 112

List of Tables

Table 1: Differentiation of Chronic Pain from Acute Pain 7

Table 2: Neuropathic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 19

Table 3: Neuropathic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2018 20

Table 4: Neuropathic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 21

Table 5: Neuropathic Pain Therapeutics Market, The US, Forecast ($bn), 2010–2018 22

Table 6: Neuropathic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 23

Table 7: Neuropathic Pain Therapeutics Market, The UK, Forecast ($m), 2010–2018 24

Table 8: Neuropathic Pain Therapeutics Market, France, Revenue ($m), 2005–2010 25

Table 9: Neuropathic Pain Therapeutics Market, France, Forecast ($m), 2010–2018 26

Table 10: Neuropathic Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 27

Table 11: Neuropathic Pain Therapeutics Market, Germany, Forecast ($m), 2010–2018 28

Table 12: Neuropathic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 29

Table 13: Neuropathic Pain Therapeutics Market, Italy, Forecast ($m), 2010–2018 30

Table 14: Neuropathic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 31

Table 15: Neuropathic Pain Therapeutics Market, Spain, Forecast ($m), 2010–2018 32

Table 16: Neuropathic Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33

Table 17: Neuropathic Pain Therapeutics Market, Japan, Forecast ($bn), 2010–2018 34

Table 18: Neuropathic Pain Therapeutics, Regulatory Filed Products, 2011 48

Table 19: Neuropathic Pain Therapeutics, Phase III Pipeline, 2011 48

Table 20: Neuropathic Pain Therapeutics, Phase II Pipeline, 2011 49

Table 21: Neuropathic Pain Therapeutics, Phase I Pipeline, 2011 50

Table 22: Neuropathic Pain Therapeutics, Discovery and Pre-Clinical Pipeline, 2011 51

Table 23: Neuropathic Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011 56

Table 24: Neuropathic Pain Therapeutics, Clinical Trials by Country, 2011 62

Table 25: Neuropathic Pain Therapeutics - Clinical Trials by Phase, 2011 63

Table 26: Neuropathic Pain Therapeutics, Clinical Trials by Status, 2011 64

Table 27: Neuropathic Pain Therapeutics, Prominent Sponsors, 2011 66

Table 28: Neuropathic Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 67

Table 29: Pfizer Inc., Pain Management, Pipeline, 2011 74

Table 30: Pfizer, Inc., Deals, 2010–2011 74

Table 31: Grunenthal GmbH, Pain Management, Pipeline, 2011 76

Table 32: Grunenthal GmbH, Deals, 2010-2011 77

Table 33: Avanir Pharmaceuticals – Pain Management, Pipeline, 2011 78

Table 34: Avanir Pharmaceuticals – Deals, 2009-2011 79

Table 35: Cephalon, Inc., Pain Management Pipeline, 2011 80

Table 36: Cephalon Inc., Deals, 2010–2011 81

Table 37: Endo Pharmaceuticals, Pain Management, Pipeline, 2011 84

Table 38: Endo Pharmaceuticals, Deals, 2011 84

Table 39: Dainippon Sumitomo Pharma Co., Ltd, Pain Management, Pipeline, 2011 85

Table 40: Dainippon Sumitomo Pharma Co., Ltd., Deals, 2011 86

Table 41: NeurogesX, Inc., Pain Management, Pipeline, 2011 89

Table 42: NeurogesX Inc., Deals, 2011 90

Table 43: Neuropathic Pain Therapeutics Market, Future Players 91

Table 44: Neuropathic Pain Therapeutics, Global, Deals, 2009-2011 99

List of Figures

Figure 1: Classification of Chronic Pain and Representative Indications 8

Figure 2: Development of Neuropathic Pain 9

Figure 3: Etiology of Neuropathic Pain 10

Figure 4: Pathophysiological Mechanisms of Neuropathic Pain 10

Figure 5: Pathophysiology of Neuropathic Pain 11

Figure 6: Sign s and Symptoms of Neuropathic Pain 12

Figure 7: Signs and Symptoms of Neuropathic Pain 13

Figure 8: Pain Measurement Scale – Faces Rating Scale 14

Figure 9: Treatment Approach in Neuropathic Pain 16

Figure 10: Neuropathic Pain Treatment Pathway 16

Figure 11: Referral Pathway for Neuropathic Pain 17

Figure 12: Neuropathic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 19

Figure 13: Neuropathic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2018 20

Figure 14: Neuropathic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 21

Figure 15: Neuropathic Pain Therapeutics Market, The US, Forecast ($bn), 2010–2018 22

Figure 16: Neuropathic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 23

Figure 17: Neuropathic Pain Therapeutics Market, The UK, Forecast ($m), 2010–2018 24

Figure 18: Neuropathic Pain Therapeutics Market, France, Revenue ($m), 2005–2010 25

Figure 19: Neuropathic Pain Therapeutics Market, France, Forecast ($m), 2010–2018 26

Figure 20: Neuropathic Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 27

Figure 21: Neuropathic Pain Therapeutics Market, Germany, Forecast ($m), 2010–2018 28

Figure 22: Neuropathic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 29

Figure 23: Neuropathic Pain Therapeutics Market, Italy, Forecast ($m), 2010–2018 30

Figure 24: Neuropathic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 31

Figure 25: Neuropathic Pain Therapeutics Market, Spain, Forecast ($m), 2010–2018 32

Figure 26: Neuropathic Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33

Figure 27: Neuropathic Pain Therapeutics Market, Japan, Revenue ($bn), 2010–2018 34

Figure 28: Opportunity and Unmet Need (Oral Drugs) in the Neuropathic Pain Therapeutics Market, 2010 36

Figure 29: Opportunity and Unmet Need (Topical Patches) in the Neuropathic Pain Therapeutics Market, 2010 37

Figure 30: Strategic Competitor Assessment of the Major Marketed Products in Neuropathic Pain, 2010 38

Figure 31: Neuropathic Pain Therapeutics – Pipeline by Phase of Development, 2011 47

Figure 32: Neuropathic Pain Therapeutics, Technology Trends Analytics Framework, 2011 53

Figure 33: Neuropathic Pain Therapeutics, Technology Trends Analytics Framework, Description, 2011 54

Figure 34: Neuropathic Pain Therapeutics, Pipeline by Mechanism of Action (%), 2011 55

Figure 35: Fentora (fentanyl buccal tablet): Chemical Structure 58

Figure 36: Nucynta ER (tapentadol): Chemical Structure 59

Figure 37: AS-3201 (ranirestat): Chemical Structure 60

Figure 38: Neuropathic Pain Therapeutics, Clinical Trials by Country, 2011 62

Figure 39: Neuropathic Pain Therapeutics, Clinical Trials by Phase (%), 2011 63

Figure 40: Neuropathic Pain Therapeutics, Clinical Trials by Status, 2011 64

Figure 41: Neuropathic Pain Therapeutics, Overall Sponsors (%), 2011 65

Figure 42: Neuropathic Pain Therapeutics, Prominent Sponsors (%), 2011 66

Figure 43: Neuropathic Pain Therapeutics, Top Companies Participating in Clinical Trials, 2011 67

Figure 44: Neuropathic Pain Therapeutics Market, Drivers and Barriers, 2011 68

Figure 45: Implications for Future Market Competition in the Neuropathic Pain Market, 2011 69

Figure 46: Neuropathic Pain Therapeutics Market, Pipeline by Company, 2011 71

Figure 47: GlobalData Market Forecasting Model 110

Companies Mentioned

Pfizer Inc.

Grunenthal GmbH

Avanir Pharmaceuticals

Cephalon Inc.

Endo Pharmaceuticals

Dainippon Sumitomo Pharma Co., Ltd.

NeurogesX Inc.

To order this report:

Hardware, Home Improvement & Furnishing Stores Industry: Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Hardware, Home Improvement & Furnishing Stores Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
2. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
3. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
4. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
5. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
6. Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
7. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
8. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):